• About
  • Meet The Team
  • Privacy Policy
Saturday, January 16, 2021

Stocks Telegraph
  • Login
  • Home
  • Featured
  • Investing
  • Morning News
  • Mid Day Movers
No Result
View All Result
Stocks Telegraph
No Result
View All Result

Why Arrowhead Pharmaceuticals (NASDAQ: ARWR) Skyrocketed Today?

by Hasnain R
September 17, 2020
in Featured
Share on FacebookShare on Twitter

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) traded up 40.33% on Wednesday after it revealed the data on the drug to treat liver disease. Arrowhead has shared the positive interim 24-week liver biopsy results in four volunteers of AROAAT2002. AROAAT2002 is the open-label phase 2 clinical study of ARO-AAT. ARO-AAT is the investigational drug that is developed for the treatment of rare-genetic liver diseases. The rare liver disease is analogous with alpha-1 antitrypsin deficiency (AATD).

The biotechnology company has revealed that the result of the study showed improvement in liver stiffness. The clinical trial has unveiled the positive effects of ARO-AAT as the company saw a reduction in intra-hepatic mutant AAT protein (Z-AAT), both Z-AAT monomer and Z-AAT polymer.  Participants have undergone the treatment for 24 weeks and all have shown the 93% to 95% drop in intrahepatic Z-AAT. Moreover, three of four patients have shown a 97% reduction in Z-AAT.

Arrowhead earlier expected that the 6 months treatment with ARO-AAT will reduce both Z-AAT monomer and Z-AAT polymer but the 24 weeks treatment data has shown the results which are more than the expectations. The company is planning to discuss with the FDA and other regulatory agencies to speed up the clinical trial.

Shares of Arrowhead Pharmaceuticals (NASDAQ: ARWR) soared 40.33% as it gained +13.63 at $47.43 during the trading session of Wednesday. In the past 52-weeks of trading, this company’s stock has fluctuated between the low range of $19.51 and a high range of $73.72. Arrowhead has traded up 143.10% from its 52-weeks low and traded down -35.66% from its 52-weeks high.  This company’s market capitalization has remained high, hitting $5.14 billion at the time of writing.

The positive result from the 24-week treatment showed that the ARO-AAT will soon improve the liver injury. This encouraging result has also given hope to the Alpha-1 community in the midst of an ongoing pandemic.

Arrowhead is currently working on the therapy, RNAi, that other companies have successfully commercialize. It has also licensed its therapies to various leading companies.  It is too early to say that it will get the EU or FDA approval but there are chances that the company will receive the approval as it has shown the positive results of phase 2 clinical study of ARO-AAT.

Arrowhead three most advanced drugs include  ARO-AAT, a treatment for liver disease. The company has recently provided promising results from its phase 2, the second one is JNJ-3989 which is licensed to Janssen and it is the potential treatment for hepatitis B. It has earlier reported the data which also showed the encouraging result. The third one is the AMG 890. AMG 890 has the ability to decrease the production of apolipoprotein A which is genetically linked with increased risk of atherosclerosis and related cardiovascular diseases.

 

Get The Best Stocks To Trade Every Day!

Join now to get the Stockstelegraph.com pre-market morning brief 100% free

Tags: AMG890AROAATArrowhead Pharmaceuticals Inc.ARWR stockClinical TrialFDAJNJ3989NASDAQ: ARWR

Related Posts

Top 15 Information Technology Stocks You Should Be Holding
Featured

Why Momo Inc (MOMO) Is Attracting Investors?

January 14, 2021
Telecom Stocks to Look Out for in 2021
Featured

Telecom Stocks to Look Out for in 2021

January 13, 2021
TG Therapeutics (NASDAQ: TGTX) Ublituximab Receives Fast Track Designation In US
Featured

Why T2 Biosystems Inc. (TTOO) is stock surging in the Pre-market hours today?

January 12, 2021
Top 20 Banking Industry Stocks For October 2020
Featured

Are These The Best Battery Stocks To Buy This Year

January 11, 2021
Blonder Tongue Receives U.S. Patent Grant For DMM Series Of Products
Featured

Can We Expect Growth From General Electric (GE) In 2021?

January 11, 2021
Beasley Broadcast Group (NASDAQ: BBGI) Announces Operating Results
Featured

Where The Li Auto (LI), XPeng (XPEV) Stocks Are Heading To

January 8, 2021
Next Post
12 Trending Stocks In Mining Industry To Watch

12 Trending Stocks In Mining Industry To Watch

Early Morning Vibes: The 4 Best Stocks To Buy Now

Blonder Tongue Receives U.S. Patent Grant For DMM Series Of Products
by Shan Zee
January 14, 2021
0

American stock markets ended trading largely in the green zone on January 13. The S&P 500 index improved to 3810...

Read more

Early Morning Vibes: Check Out These 4 hot Stocks Right Now

GILT Stock
by Shan Zee
January 12, 2021
0

On January 11, American stock markets closed in the red. The S & P500 index fell 0.66% to 3800 points,...

Read more

Early Morning Vibes: Watch These 4 Stocks Today

Beasley Broadcast Group (NASDAQ: BBGI) Announces Operating Results
by Shan Zee
January 13, 2021
0

The US stock indexes were traded in small ranges on January 12. The S&P 500 has risen symbolically by 0.04%...

Read more

Early Morning Vibes: 4 Stocks We Like for Friday

by Shan Zee
January 15, 2021
0

On January 14, the American stock indices closed in the red. The S&P 500 index dropped 0.38% to 3796 points,...

Read more

Early Morning Vibes: 4 Top Trending Stocks To Watch For Monday

GEVO Inc [GEVO]  – A Top Stock To Watch For The Remainder Of 2020
by Shan Zee
January 11, 2021
0

Last week indices in the United States managed to set fresh records on the price boards. Interestingly, we saw Wall...

Read more
  • About
  • Meet The Team
  • Privacy Policy

© 2020 Stocks Telegraph - All Rights Reserved

No Result
View All Result
  • Home
  • Featured
  • Investing
  • Morning News
  • Mid Day Movers

© 2020 Stocks Telegraph - All Rights Reserved

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Get The Best Stocks To Trade Every Day!

Join now to get the Stockstelegraph.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.